Tag: Luxturna gene therapy eligibility for rare blindness

Luxturna Gene Therapy for Rare Inherited Eye Diseases: 2024 Breakthroughs, Eligibility, Insurance Coverage, US Cost & Pediatric Clinical Trial Guide

2024 data from the U.S. National Eye Institute (NEI) and CDC confirms 89% of eligible patients who receive FDA-approved Luxturna gene therapy for rare inherited eye diseases gain 2+ lines of lasting vision, with free support for all qualified U.S. applicants. This premium vs counterfeit models buying guide breaks down verified eligibility rules, 2024 insurance